Publications by authors named "V Di Nunno"
Drugs targeting mitochondrial energy metabolism are emerging as promising antitumor therapeutics. Glioma treatment is extremely challenging due to the high complexity of the tumor and the high cellular heterogeneity. From a metabolic perspective, glioma cancer cells can be classified into the oxidative metabolic phenotype (mainly depending on mitochondrial respiration for energy production) and glycolytic phenotype or "Warburg effect" (mainly depending on glycolysis).
View Article and Find Full Text PDF: Glioblastoma -wildtype (GBM -wt) is the most aggressive brain tumor in adults and is characterized by an immunosuppressive microenvironment. Different factors shaping its tumor microenvironment (TME) regulate tumor progression and treatment response. The aim of this study was to characterize the main immunosuppressive elements of the GBM -wt TME.
View Article and Find Full Text PDFHuman papilloma virus (HPV) infection is responsible for 4.5% of cancers worldwide, i.e.
View Article and Find Full Text PDFArticle Synopsis
- A systematic review and meta-analysis revealed that economic income significantly affects the survival rates of glioblastoma patients, with those having lower income experiencing poorer outcomes.
- The study analyzed 12 research papers, encompassing over 143,000 patients, and found that a lower economic income correlated with a hazard ratio of 1.09, indicating a higher risk of mortality.
- Factors like the type of healthcare system and the timing of treatment had no significant impact on survival, highlighting the need to address socioeconomic disparities in cancer care to improve outcomes for disadvantaged patients.
Purpose Of Review: In this review, we investigated the role of European oncological networks on management and care of patients with central nervous system (CNS) malignancies.
Recent Findings: Within this universe of tumors, malignancies of the central nervous system (CNS) malignancies represent a challenge because of several reasons such as biological complexity, the need of dedicated experienced physicians (surgeons, pathologists, radiologists and neuro-oncologists) and tertiary healthcare providers. Limits to the development of effective and innovative care are represented by the rarity of these tumors and their extreme heterogeneity in terms of clinical presentation, course of the disease, genetic assessments and site of presentation.